Orvacabtagene autoleucel

Unassigned

New Medicines

Relapsed or refractory multiple myeloma (MM) - fourth-line or greater

Information

Advanced therapy medicinal product (ATMP)
Celgene
Celgene

Development and Regulatory status

None
None
Phase II Clinical Trials

Category

B-cell maturation antigen (BCMA) targeting chimeric antigen receptor T cell (CAR-T) therapy
The incidence in Europe is 4.5-6.0 per 100,000/year with a mortality rate of 4.1 per 100,000/year [1].
Relapsed or refractory multiple myeloma (MM) - fourth-line or greater
Intravenous